- Home
- PBFS vs TERN Comparison
PBFS vs TERN Comparison
Compare PBFS & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBFS
- TERN
- Stock Information
- Founded
- PBFS 1889
- TERN 2017
- Country
- PBFS United States
- TERN United States
- Employees
- PBFS N/A
- TERN N/A
- Industry
- PBFS Banks
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- PBFS Finance
- TERN Health Care
- Exchange
- PBFS Nasdaq
- TERN Nasdaq
- Market Cap
- PBFS 278.5M
- TERN 310.8M
- IPO Year
- PBFS N/A
- TERN 2021
- Fundamental
- Price
- PBFS $11.63
- TERN $3.04
- Analyst Decision
- PBFS
- TERN Buy
- Analyst Count
- PBFS 0
- TERN 5
- Target Price
- PBFS N/A
- TERN $18.38
- AVG Volume (30 Days)
- PBFS 12.7K
- TERN 1.0M
- Earning Date
- PBFS 05-20-2025
- TERN 05-08-2025
- Dividend Yield
- PBFS N/A
- TERN N/A
- EPS Growth
- PBFS 27.31
- TERN N/A
- EPS
- PBFS 0.80
- TERN N/A
- Revenue
- PBFS $88,641,000.00
- TERN N/A
- Revenue This Year
- PBFS N/A
- TERN N/A
- Revenue Next Year
- PBFS N/A
- TERN N/A
- P/E Ratio
- PBFS $14.54
- TERN N/A
- Revenue Growth
- PBFS 21.19
- TERN N/A
- 52 Week Low
- PBFS $8.97
- TERN $1.87
- 52 Week High
- PBFS $12.20
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- PBFS 56.62
- TERN 51.89
- Support Level
- PBFS $11.09
- TERN $2.93
- Resistance Level
- PBFS $11.84
- TERN $3.62
- Average True Range (ATR)
- PBFS 0.33
- TERN 0.25
- MACD
- PBFS 0.06
- TERN 0.03
- Stochastic Oscillator
- PBFS 78.57
- TERN 39.27
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.